By admin 
The unfolding controversy surrounding the American Diabetes Association (ADA) and its handling of member expulsions during its annual scientific sessions has taken a sharp and unexpected turn, as the organization’s own oversight body admits that its initial investigation was fundamentally incomplete. Three months after the dramatic removal of five members from the New Orleans conference on June 5, the story is far from over, evolving from a localized security incident into a full-scale crisis of institutional governance and transparency. On September 1, the ADA had initially issued what it termed "top-line findings" from an internal panel tasked with reviewing the incident, which involved the calling of the New Orleans Police Department to remove clinicians and advocates from the venue. While that initial summary appeared to be an attempt to close the book on the matter, the ADA’s Audit and Governance Committee (AGC) took the extraordinary step this past Sunday of notifying the Board of Directors that the investigation remains active and that previous conclusions may have been premature.
According to a release issued by the ADA, the AGC has informed the Board that the initial findings failed to account for the "full breadth and depth" of the investigation. Most notably, the committee revealed that critical interviews were conducted after the initial report had already been prepared and disseminated, suggesting a disconnect between the investigative process and the executive communication of its results. The Sunday statement was blunt in its implications: "Additional findings are expected to be presented to the Board, which may clarify or correct information previously provided and could result in further actions by the Board." This admission of potential inaccuracies in the initial review has sent shockwaves through the diabetes community, raising questions about whether the ADA was originally attempting to downplay the severity of the incident or if there was a breakdown in internal communication that led to an incomplete narrative being presented to the public.
The core of the controversy traces back to the ADA’s 82nd Scientific Sessions held in New Orleans. On the morning of June 5, five individuals—all of whom were registered attendees and members of the association—were forcibly removed from the convention center. The group, which included prominent physicians and insulin affordability advocates, had reportedly been engaging in a peaceful demonstration or questioning the ADA’s relationship with major pharmaceutical manufacturers during a session. The decision to involve the New Orleans Police Department (NOPD) was seen by many in the medical community as an unprecedented escalation. In professional scientific circles, disagreements over policy, pharmaceutical funding, and clinical guidelines are typically handled through academic debate or internal grievance procedures, not through the use of municipal law enforcement. The sight of doctors and researchers being escorted out of a scientific conference by armed police officers created an immediate PR nightmare for the ADA, fueling accusations that the organization was prioritizing its corporate sponsors over the safety and free speech of its members.
The initial September 1 report released by the ADA denied that the organization had censored the opinions of the expelled members. It defended the removal as a necessary measure for security and the orderly conduct of the conference. However, the lack of transparency—specifically the decision to keep the full review confidential—drew immediate criticism from the ADA’s broader membership. Critics argued that a "top-line summary" written by the organization itself was insufficient to address the gravity of the situation. The recent backtrack by the AGC suggests that the internal pushback may have been more significant than the Board anticipated. By admitting that the investigation did not take into account the "full breadth and depth" of the situation, the AGC has essentially validated the concerns of those who felt the initial report was a "whitewash" designed to protect the organization’s leadership.
To understand the weight of this development, one must look at the broader context of the ADA’s role in the global health landscape. The ADA is the world’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. Its annual Scientific Sessions are the premier global event for diabetes research, attracting thousands of clinicians, researchers, and industry representatives. Because the ADA sets the "Standards of Medical Care in Diabetes"—the gold-standard guidelines used by doctors worldwide—its internal culture and governance have direct implications for patient care. When the organization is accused of silencing dissent or using heavy-handed security tactics against its own members, it calls into question the integrity of the consensus-building process that informs its clinical guidelines.
The "New Orleans Five," as the expelled members have come to be known in social media circles, were primarily focused on the issue of insulin pricing—a flashpoint in American healthcare. For years, the ADA has walked a fine line between advocating for affordable drug prices and maintaining its financial relationships with the "Big Three" insulin manufacturers: Eli Lilly, Novo Nordisk, and Sanofi. These companies are major sponsors of the ADA’s programs and conferences. Advocates have long argued that the ADA has been too timid in its criticism of high insulin costs, fearing that more aggressive stances might alienate its corporate donors. The June 5 incident was viewed by many as the physical manifestation of this tension. The expulsion of members who were vocal about pricing issues was interpreted not as a security necessity, but as a symbolic act of protection for the status quo.
The AGC’s latest update suggests that the "certain interviews" conducted after the initial findings may have provided a different perspective on the events of June 5. These interviews likely included the expelled members themselves, as well as eyewitnesses who may have contradicted the official security narrative. If these new findings "clarify or correct" the previous report, the ADA Board may be forced to issue a formal apology, reconsider its security protocols, or even face leadership changes. The mention of "further actions" by the Board hints at the possibility of disciplinary measures against those who authorized the police intervention or those who rushed the initial, incomplete report to the public.
From a governance perspective, the AGC’s decision to break ranks with the initial findings is a significant move. In most large non-profits, the Audit and Governance Committee serves as a watchdog, ensuring that the organization adheres to its bylaws and ethical standards. By publicly stating that the Board’s information was incomplete, the AGC is asserting its independence. This internal friction indicates a divide within the ADA’s leadership between those who want to move past the scandal quickly and those who believe that only full transparency can restore the organization’s credibility. The stakes are high; the ADA relies on the trust of its professional members to maintain its influence. If clinicians feel that the ADA is an environment where dissent is met with police intervention, they may take their research and their membership dues elsewhere, such as to the European Association for the Study of Diabetes (EASD) or other specialized medical societies.
Furthermore, the legal implications of the expulsion remain a looming threat. Private organizations do have the right to manage their events and remove individuals who violate codes of conduct. However, the use of police to remove members without clear evidence of a threat or a breach of the peace can lead to claims of wrongful expulsion, defamation, or civil rights violations, especially if the removal was based on the content of the members’ speech. By reopening the investigation, the ADA may be attempting to mitigate legal risk by ensuring that its final stance is supported by a comprehensive and defensible factual record.
The medical community’s reaction to the Sunday release has been one of cautious skepticism. Many are waiting to see if the "additional findings" will actually be made public or if they will remain hidden behind the same wall of confidentiality that obscured the first report. Transparency is the only currency that can buy back trust in this scenario. For the ADA to move forward, experts suggest it must provide a detailed account of who made the call to the NOPD, what specific actions by the members triggered that call, and why less restrictive measures—such as a formal warning or a private mediation—were not utilized.
As the ADA prepares for its next set of board meetings, the shadow of New Orleans continues to loom large. The organization finds itself at a crossroads: it can either double down on its defensive posture or embrace a new era of radical transparency that acknowledges the right of its members to challenge the institution from within. The fact that the story is "not over" three months later is a testament to the persistence of the advocates involved and the inherent difficulty of suppressing dissent in the digital age. The upcoming findings from the Audit and Governance Committee will likely determine the ADA’s trajectory for years to come, signaling whether it remains a top-down bureaucracy or returns to its roots as a member-driven advocacy powerhouse. For now, the diabetes world remains in a state of watchful waiting, looking for the "clarification and correction" that was promised, and hoping that the final chapter of the New Orleans incident reflects the scientific and ethical standards the ADA claims to uphold.
